Sundowing and circadian rhythm disorders in dementia

Acta Neurologica Belgica

Volumn 106, Issue 4, 2006, Pages 168-175

  Klaffke, S ^a   Staedt, Juergen ^a,b  

^a VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^b NONE   (Germany)

Author keywords

Bright light therapy; Dementia; Melatonin; Neuroleptics; Old age; PLMS; Sleep disorder; Sundowning

Indexed keywords

CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; MELATONIN; PERGOLIDE; PLACEBO; PRAMIPEXOLE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR;

ACTIMETRY; AGING; ALCOHOL ABSTINENCE; ALZHEIMER DISEASE; CHOLINERGIC ACTIVITY; CIRCADIAN RHYTHM SLEEP DISORDER; DELUSIONAL DISORDER; DEMENTIA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MEYNERT BASAL NUCLEUS; NEUROPATHOLOGY; NOCTURIA; NONREM SLEEP; OBESITY; PHOTOTHERAPY; REM SLEEP; REST; RESTLESS LEGS SYNDROME; REVIEW; RISK FACTOR; SENILE DEMENTIA; SLEEP APNEA SYNDROME; SLEEP DISORDER; SUNDOWNING; WEIGHT CONTROL; AGED; BRAIN CORTEX; CHOLINERGIC NERVE; DARKNESS; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SLEEP; STANDARD;

AGED; BASAL NUCLEUS OF MEYNERT; CEREBRAL CORTEX; CHOLINERGIC FIBERS; CHOLINESTERASE INHIBITORS; CHRONOBIOLOGY DISORDERS; DARKNESS; DEMENTIA; HUMANS; PHOTOTHERAPY; SLEEP; SLEEP DISORDERS;

EID: 33846975813     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Aarsland D, Laake K, Larsen J. P., Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J. Neurol. Neurosurg. Psychiatry, 2002, 72: 708-712.
2. Ancoli-Israel S., Kripke D. F., Klauber M. R., Fell R., Stepnowsky C. et al. Periodic limb movements in sleep in community dwelling elderly. Sleep, 1991, 14: 496-500.
3. Ancoli-Israel S., Kripke D. F. Now I lay me down to sleep: the problem of sleep fragmentation in the elderly and demented residents of nursing homes. Bull. Clin. Neurosci., 1989, 1154: 127-132.
4. Ancoli-Israel S., Martin J. L., Gehrivian P., Shochat T., Marler M. et al. Effect of light on agitation in institutionalized patients with severe Alzheimer disease. Am. J. Geriatr Psychiatry, 2003, 11: 194-203.
5. Ancoli-Israel S., Cole R., Alessi C., Chambers M., Moorcroft W. et al. The role of actigraphy in the study of sleep and circadian rhythms. Sleep, 2003, 26: 342-392.
6. Asayama K., Yamadera H., Ito T., Suzuki H., Kudo Y. et al. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and noncognitive functions in Alzheimer type dementia. J. Nippon Med. Sch., 2003, 70: 334-341.
7. Ayalon L., Ancoli-Israel S., Stepnowsky C., Marler M., Palmer B.W. et al. Adherence to continuous positive airway pressure treatment in patients with Alzheimer's disease and obstructive sleep apnea. Am. J. Geriatr. Psychiatry, 2006, 14: 176-180.
8. Barinaga M. How jet-lag hormone does double duty in the brain. Science, 1997, 277: 480.
9. Bassetti C, Aldrich M. S., Chervin R. D., Quind D. Sleep apnea in patients with transient ischemic attack and stroke. Neurology, 1996, 47: 1167-1173.
10. Belenky M. A., Pickard G. E. Subcellular distribution of 5-HT(1B) and 5-HT(7) receptors in the mouse suprachiasmatic nucleus. Comp. Neurol., 2001, 432: 371-388.
11. Black S., Roman G. C., Geldmacher D. S., Salloway S., Hecker J. et al. Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke, 2003, 34: 2323-2330.
12. Bliwise D. L., What is sundowning? J. Am. Geriatr. Soc., 1994, 42: 1009-1011.
13. Bliwise D. L., Hughes M., McMahon P. M., Kutner N. Observed sleep/ wakefulness and severity of dementia in an Alzheimer's disease special care unit. J. Gerontol. A Biol. Sci. Med. Sci., 1995, 50: 303-306.
14. Bliwise D. L., Adelman C. L., Ouslander J. G. Polysomnographic correlates of spontaneous nocturnal wetness episodes in incontinent geriatric patients. Sleep, 2004, 27: 153-157.
15. Bullock R. Cholinesterase inhibitors and vascular dementia: another string to their bow? CNS Drugs, 2004, 18: 79-92.
16. Burgio L. D., Scilley K., Hardin J. M., Hsu C. Temporal patterns of disruptive vocalization in elderly nursing home residents. Int. J. Geriatr. Psychiatry, 2001, 16: 378-386.
17. Burns A., Spiegel R., Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Int. J. Geriatr. Psychiatry, 2004, 19: 243-249.
18. Cacabelos R., Rodriguez B., Carrera C., Caamano J., Beyer K. et al. APOE-related frequency of cognitive and noncognitive symptoms in dementia. Methods Find Exp. Clin. Pharmacol., 1996, 18: 693-706.
19. Cardinali D. P., Brusco L. I., Liberczuk C., Furio A. M. The use of melatonin in Alzheimer's disease. Neuroendocrinol. Lett., 2002, 23: 20-23.
20. Coen R. F., Swanwick G. R., O'Boyle C. A., Coakley D. Behaviour disturbance and other predictors of carer burden Alzheimer's disease. Int. J. Geriatr. Psychiatry, 1997, 12: 331-336.
21. Erkinjuntti T., Kurz A., Gauthier S., Bullock R., Lilienfeld S. et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet, 2002, 359: 1283-1290.
22. Evans L. K. Sundown syndrome in institutionalized elderly. J. Am. Geriatr Soc., 1987, 35: 101-108.
23. Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P. et al. Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology, 2001, 57: 613-620.
24. Finkel S., Kozma C., Long S., Greenspan A., Mahmoud R. et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int. Psychogeriatr., 2005, 17: 617-629.
25. Foley D. J., Monjan A. A., Brown S. L., Simonsick E. M., Wallace R. B. et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep, 1995, 18: 425-432.
26. Fontana Gasio P. F., Krauchli K., Cajochen C., Someren E., Amrhein I. et al. Dawn-dusk simulation light therapy of disturbed circadian rest-activity cycles in demented elderly. Experiment Gerontol., 2003, 38: 207-216.
27. Gallagher-Thompson D., Brooks J. O. III, Bliwise D., Leader J., Yesavage J. A. The relations among caregiver stress, "sundowning" symptoms, and cognitive decline in Alzheimer's disease. J. Am. Geriatr Soc., 1992, 40: 807-810.
28. Gorfine T., Assaf Y, Goshen-Gotistein Y., Yeshuruh J., Zisapel N. Sleep-anticipating effects of melatonin in the human brain. Neuroimage, 2006, 31: 410-418.
29. Grassel E. Warum pflegen Angehörige? Ein Pflege-modell für die häusliche Pflege im höheren Lebensalter. Zschr. Gerontopsychol. & Psychiatr., 2000, 13: 85-94.
30. Graf A., Wallner C., Schubert V., Willeit M., Wlk W. et al. The effects of light therapy on mini-mental state examination scores in demented patients. Biol. Psychiatry, 2001, 50: 725-727.
31. Haffmans P. M., Sival R. C., Lucius S. A., Cats Q., Van Gelder L. Bright light therapy and melatonin in motor restless behaviour in dementia: a placebo-controlled study. Int. J. Geriatr. Psychiatry, 2001, 16: 106-110.
32. Horiguchi J., Yamashita H., Mizuno S., Kuramato Y., Kagaya A. et al. Nocturnal eating/drinking syndrome and neuroleptic-induced restless legs syndrome. Int. Clin. Psych. Opharmacol., 1999, 14: 33-36.
33. Jelicic M., Bosma H., Ponds R. W., Van Boxtel M. P., Houx P. J. et al. Subjective sleep problems in later life as predictors of cognitive decline. Report from the Maastricht Ageing Study (MAAS). Int. J. Geriatr Psychiatry, 2002, 17: 73-77.
34. Jellinger K. Alterations of muscarinic acetylcholine receptor subypes in diffuse Lewy body disease: relation to Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 2000, 68: 253-254.
35. Jin X., Von Gall C., Pieschl R. L., Gribkoff V. K., Stehle J.H. et al. Targeted disruption of the mouse Mel(l b) melatonin receptor. Mol. Cell. Biol., 2003, 23: 1054-1060.
36. Kozma C. M., Engelhart L. M., Long S., Greenspan A., Mahmoud R. et al. Absence of increased relative stroke risk in elderly dementia patients treated with risperidone versus other antipsychotics. ICGP Programm book 2003. www.icgp.org/1CGP_2003_programm_book.pdf73.
37. Kraus T., Schuld A., Pollmacher T. Restless legs syndrome probably caused by olanzapine. J. Clin. Psych. Opharmacol., 1999, 19: 478-479.
38. Kumar A. M., Tims F., Cruess D. G., Mintzer M. J., Ironson G. et al. Music therapy increases melatonin levels in patients with Alzheimer's disease. Altern Ther. Health Med., 1999, 5: 49-57.
39. Kurz A. F., Erkinjuntti T., Small G. W., Lilienfeld S., Damaraju C. R. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. Eur J. Neurol., 2003, 10: 633-640.
40. Lavie P. Melatonin: role in gating nocturnal rise in sleep propensity. J. Biol. Rhythms, 1997, 12: 627-665.
41. Liperoti R., Gambassi C., Lapane K. L., Chiang C., Pedone C. et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J. Clin. Psychiatry, 2005, 66: 1090-1096.
42. Liu C., Weaver D. R., Jin X., Shearman L. P., Pieschl R. L. et al. Molecular dissection of two distinct actions of melatonin on suprachiasmatic circadian clock. Neuron, 1997, 19: 91-102.
43. King M. A., Jaffre M. O., Morrish E., Shneerson J. M., Smith I. E. The validation of a new actigraphy system for the measurement of periodic leg movements in sleep. Sleep Medicine, 2005, 6: 1-7.
44. Lyketsos C. G., Lindell Veiel L., Baker A., Steele C. A randomized, controlled trail of bright light therapy for agitated behaviours in dementia patients residing in long-term care. Int. J. Geriatr. Psychiatry, 1999, 14: 520-525.
45. Madeira M. D., Pereira P. A., Silva S. M., Cadete-Leite A., Paulabarbosa M. M. Basal forebrain neurons modulate the synthesis and expression of neuropeptides in the rat suprachiasmatic nucleus. Neuroscience, 2004, 125: 889-901.
46. Malouf R., Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst. Rev., 2004, CD004395.
47. Martin J., Marler M., Shochat T., Ancoli-Israel S. Circadian rhythms of agitation in institutionalized patients with Alzheimer's disease. Chronobiol. Int., 2000, 17: 405-418.
48. Martin J. L., Mory A. K., Alessi C. A. Nighttime oxygen desaturation and symptoms of sleep-disordered breathing in long-stay nursing home residents. J. Gerontol. A Biol. Sci. Med. Sci., 2005, 60: 104-108.
49. McGeer P. L., McGeer E. G., Suzuki J., Dolman C. E., Nagai T. Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain. Neurology, 1984, 34: 741-745.
50. McKeith I. G., Grace J. B., Walker Z., Byrne E. J., Wilkinson D. et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int. J. Geriatr. Psychiatry, 2000, 15: 387-392.
51. Miller J. D. On the nature of the circadian clock in mammals. Am. J. Physiol., 1993, 264: 821-832.
52. Mishima K., Okawa M., Shimizu T., Hishikawa Y. Diminished melatonin secretion in the elderly caused by insufficient environmental illumination. J. Clin. Endocrinol. Metabol., 2001, 186: 129-134.
53. Montplaisir J., Nicolas A., Denesle R., Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurol. Clin., 1996, 14: 629-650.
54. Moretti R., Torre P., Antonello R. M., Cazzato G., Bava A. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am. J. Alzheimers Dis. Other Demen., 2003, 18: 265-272.
55. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study 2001. Pathological correlates of late-onset dementia in a multicenter, community-based population in England and Wales. Lancet, 2001, 357: 169-175.
56. Nunez A. Unit activity of rat basal forebrain neurons: relationship to cortical activity. Neuroscience, 1996, 72: 757-766.
57. Obler S. K. Leg symptoms in outpatient veterans. West J. Med., 1991, 155: 256.
58. Okumoto Y, Koyama E., Matsubara H., Nakano T., Nakamura R. Sleep improvement by light in a demented aged individual. Psychiatry Clin. Neurosci., 1998, 52: 194-196.
59. Perry R., McKeith I, Perry E. Lewy body dementia - clinical, pathological and neurochemical interconnections. J. Neural. Transm., 1997, Suppl. 51: 95-109.
60. Pollak C. P., Perlick D., Linsner J. P., Wenston J., Hsieh F. Sleep problem in the community elderly as predictors of death and nursing home placement. J. Commun. Hlth., 1990, 15: 123-135.
61. Reinikainen K. J., Riekkinen P. J., Paljärvi L., Soininen H., Helkala L. et al. Cholinergic deficit in Alzheimer's disease: a study based on CSF and autopsy data. Neurochem. Res., 1988, 13: 135-146.
62. Riekkinen Jr. J., Sirvio J., Riekkinen P. Relation between EEG delta power and the cortical choline acetyl-transferase content. Neurosci. Res., 1990, 8: 12-20.
63. Samuel W., Caligiuri M., Galasko D., Lacro J., Marini M. et al. Better cognitive and psycho pathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int. J. Geriatr. Psychiatry, 2000, 15: 794-802.
64. Satlin A., Volicer L., Ross V., Herz L., Campbell S. Bright light treatment of behavioural and sleep disturbances in patients with Alzheimer's disease. Am. J. Psychiatry, 1992, 149: 1028-1032.
65. Serfaty M., Kennell-Webb S., Warner J., Blizard R., Raven P. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int. J. Geriatr Psychiatry, 2002, 17: 1120-1127.
66. Sforza E., Johannes M., Claudio B. The PAM-RL ambulatory device for detection of periodic leg movements: a validation study. Sleep Med., 2005, 6: 407-413.
67. Shochat T., Martin J., Marler M., Ancoli-Israel S. Illumination levels in nursing home patients: effects on sleep and activity rhythms. J. Sleep Res., 2000, 9: 373-337.
68. Singer C., Tractenberg R. E., Kaye J., Schafer K., GAMST A. et al. Alzheimer's Disease Cooperative Study. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep, 2003, 26: 893-901.
69. Staedt J., Stoppe G., Kogler A., Riemann H., Hajak G. et al. Nocturnal myoclonus syndrome (periodic movements in sleep) related to central dopamine D2-receptor alteration. Eur Arch. Psychiatry Clin. Neurosci., 1995, 245: 8-10.
70. Staedt J., Hunerjager H., Ruther E., Stoppe G. Pergolide: Treatment of choice in Restless Legs Syndrome (RLS) and Nocturnal Myocionus Syndrome (NMS). Longterm follow up on pergolide. J. Neural. Transm., 1998, 105: 265-268.
71. Steriade M. Acetylcholine systems and rhythmic activities during the waking-sleep cycle. Prog. Brain Res., 2004, 145: 179-196.
72. Stoppe G., Brandt C., Staedt J. Behavioural problems associated with dementia: the role of newer antipsychotics. Drugs & Aging, 1999, 14: 41-54.
73. Tractenberg R. E., Singer C. M., Cummings J. L., Thal U. The sleep disorders inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease. J. Sleep Res., 2003, 12: 331-337.
74. Teri L., Logsdon R.G., McCurry S.M. Nonpharmacologic treatment of behavioural disturbance in dementia. Med. Clin. North Am., 2002, 86: 641-656.
75. Trinh N. H., Hoblyn J., Mohanty S., Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. J. Am. Med. Ass., 2003, 289: 210-216.
76. Van Someren E. J., Kessler A., Mirmiran M., Swaab D. F. Indirect bright light improves circadian rest-activity rhythm disturbances in demented patients. Biol. Psychiatry, 1997, 41: 955-963.
77. Volicer L., Harper D. G., Manning B. C., Goldstein R., Satlin A. Sundowning and circadian rhythms in Alzheimer's disease. Am. J. Psychiatry, 2001, 158: 704-711.
78. Wetter T. C., Brunner J., Bronisch T. Restless legs syndrome probably induced by risperidone treatment. Pharmacopsychiatry, 2002, 35: 109-111.
79. Wilkinson D., Doody R., Helme R., Taubman K., Mintzer J. et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology, 2003, 61: 479-86.
80. Wu Y. H., Feenstra M. G., Zhou J. N., Liu R. Y., Torano J. S. et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer's disease: alterations in preclinical und clinical stages. J. Clin. Endocrinol. Metab., 2003, 88: 5898-5906.
81. Wu Y. H., Swaab D. F. The human pineal gland and melatonin in aging and Alzheimer's disease. J. Pineal. Res., 2005, 38: 145-152.
82. Wyatt J. K., Duk D. J., Ritz-De Cecco A., Ronda J. M., Czeisler C. A. Sleep-facilitating effect of exoge nous melatonin in healthy young men and women is circadian-phase dependent. Sleep, 2006, 29: 609-618.
83. Yamadera H., Ito T., Suzuki H., Asayama K., ITO R. et al. Effects of bright light on cognitive and sleepwake (circadian) rhythm disturbances in Alzheimer-type dementia. Psychiatry Clin. Neurosci., 2000, 54: 352-352.
84. Yang C., White D. P., Winkelman J. W. Antidepressants and periodic leg movements of sleep. Biol. Psychiatry, 2005, 58: 510-514.
85. Yoon I. Y., Kripke D. F., Elliott J. A., Youngsted S. D., Rex K. M. et al. Age-related changes of circadian rhythms and sleep-wake cycles. Am. Geriatr Soc., 2003, 51: 1085-1091.
86. Yuen E. J., Zisselman M. H., Louis D. Z., Rovner B. W. Sedative-hypnotic use by the elderly: Effects on hospital length of stay and costs. J. Ment. Hlth. Administr., 1997, 24: 90-97.